Role of Systemic Immunoinflammation Landscape in the Overall Survival of Patients with Leptomeningeal Metastases from Lung Cancer

References

• Le Rhun E, Weller M, Brandsma D, et al. EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017;28(suppl_4):iv84–iv99. doi:10.1093/annonc/mdx221
   PubMedGoogle Scholar
• Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol. 2018;19(1):e43–e55. doi:10.1016/S1470-2045(17)30689-7
   PubMed Web of Science ®Google Scholar
• Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL. Current approaches to the management of brain metastases. Nat Rev Clin Oncol. 2020;17(5):279–299. doi:10.1038/s41571-019-0320-3
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Yang TJ, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 2017;3(6):827–831. doi:10.1001/jamaoncol.2016.3834
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Preusser M, van den Bent M, Andratschke N, Weller M. How we treat patients with leptomeningeal metastases. ESMO Open. 2019;4(Suppl 2):e000507. doi:10.1136/esmoopen-2019-000507
   PubMedGoogle Scholar
• Alexander M, Lin E, Cheng H. Leptomeningeal metastases in non-small cell lung cancer: optimal systemic management in NSCLC with and without driver mutations. Curr Treat Options Oncol. 2020;21(9):72. doi:10.1007/s11864-020-00759-3
   PubMed Web of Science ®Google Scholar
• Ozcan G, Singh M, Vredenburgh JJ. Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments. Clin Cancer Res. 2022;29:11–29.
   Web of Science ®Google Scholar
• Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345–359. doi:10.1038/s41568-021-00347-z
   PubMed Web of Science ®Google Scholar
• Nost TH, Alcala K, Urbarova I, et al. Systemic inflammation markers and cancer incidence in the UK Biobank. Eur J Epidemiol. 2021;36(8):841–848. doi:10.1007/s10654-021-00752-6
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830 e814. doi:10.1016/j.immuni.2018.03.023
   PubMed Web of Science ®Google Scholar
• Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci. 2017;20(2):136–144. doi:10.1038/nn.4475
   PubMed Web of Science ®Google Scholar
• Ferrucci PF, Ascierto PA, Pigozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27(4):732–738. doi:10.1093/annonc/mdw016
   PubMed Web of Science ®Google Scholar
• Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74. doi:10.1186/s40425-018-0383-1
   PubMed Web of Science ®Google Scholar
• Li Q, Lin Z, Hong Y, et al. Brain parenchymal and leptomeningeal metastasis in non-small cell lung cancer. Sci Rep. 2022;12(1):22372. doi:10.1038/s41598-022-26131-z
   PubMedGoogle Scholar
• Vavala T, Menis J. Editorial: brain and leptomeningeal metastases in lung cancer. Front Oncol. 2022;12:1115126. doi:10.3389/fonc.2022.1115126
   PubMedGoogle Scholar
• Hong Y, Duan P, He L, et al. Systematic immunological level determined the prognosis of leptomeningeal metastasis in lung cancer. Cancer Manag Res. 2022;14:1153–1164. doi:10.2147/CMAR.S347323
   PubMed Web of Science ®Google Scholar
• Cai HQ, Liu AS, Zhang MJ, et al. Identifying predictive gene expression and signature related to temozolomide sensitivity of glioblastomas. Front Oncol. 2020;10:669. doi:10.3389/fonc.2020.00669
   PubMed Web of Science ®Google Scholar
• Yuan Q, Wang SQ, Zhang GT, et al. Highly expressed of SERPINA3 indicated poor prognosis and involved in immune suppression in glioma. Immun Inflamm Dis. 2021;9(4):1618–1630. doi:10.1002/iid3.515
   PubMed Web of Science ®Google Scholar
• Jiang BY, Li YS, Guo WB, et al. Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells. Clin Cancer Res. 2017;23(18):5480–5488. doi:10.1158/1078-0432.CCR-17-0047
   PubMed Web of Science ®Google Scholar
• Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised Phase 3 trial. Lancet. 2017;390(10089):29–39. doi:10.1016/S0140-6736(17)30565-2
   PubMed Web of Science ®Google Scholar
• Nanjo S, Hata A, Okuda C, et al. Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. Br J Cancer. 2018;118(1):32–37. doi:10.1038/bjc.2017.394
   PubMed Web of Science ®Google Scholar
• Hendriks LEL, Bootsma G, Mourlanette J, et al. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. Eur J Cancer. 2019;116:182–189. doi:10.1016/j.ejca.2019.05.019
   PubMed Web of Science ®Google Scholar
• Naidoo J, Schreck KC, Fu W, et al. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. J Immunother Cancer. 2021;9(8):e002473. doi:10.1136/jitc-2021-002473
   PubMed Web of Science ®Google Scholar
• Waki F, Ando M, Takashima A, et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol. 2009;93(2):205–212. doi:10.1007/s11060-008-9758-3
   PubMed Web of Science ®Google Scholar
• Yan W, Jing W, An N, et al. The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute. Cancer Med. 2019;8(6):2769–2776. doi:10.1002/cam4.2156
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Wallet J, Mailliez A, et al. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. Neuro Oncol. 2020;22(4):524–538. doi:10.1093/neuonc/noz201
   PubMed Web of Science ®Google Scholar
• Palmisciano P, Watanabe G, Conching A, Ogasawara C, Vojnic M, D’Amico RS. Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials. J Neurooncol. 2022;160(1):79–100. doi:10.1007/s11060-022-04118-0
   PubMed Web of Science ®Google Scholar
• Valiente M, Ahluwalia MS, Boire A, et al. The evolving landscape of brain metastasis. Trends Cancer. 2018;4(3):176–196. doi:10.1016/j.trecan.2018.01.003
   PubMed Web of Science ®Google Scholar
• Boire A, Brastianos PK, Garzia L, Valiente M. Brain metastasis. Nat Rev Cancer. 2020;20(1):4–11. doi:10.1038/s41568-019-0220-y
   PubMed Web of Science ®Google Scholar
• Soffietti R, Ahluwalia M, Lin N, Ruda R. Management of brain metastases according to molecular subtypes. Nat Rev Neurol. 2020;16(10):557–574. doi:10.1038/s41582-020-0391-x
   PubMed Web of Science ®Google Scholar
• Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–1284. doi:10.1101/gad.314617.118
   PubMed Web of Science ®Google Scholar
• Shaked Y. The pro-tumorigenic host response to cancer therapies. Nat Rev Cancer. 2019;19(12):667–685. doi:10.1038/s41568-019-0209-6
   PubMed Web of Science ®Google Scholar
• Lin YJ, Wei KC, Chen PY, Lim M, Hwang TL. Roles of neutrophils in glioma and brain metastases. Front Immunol. 2021;12:701383. doi:10.3389/fimmu.2021.701383
   PubMed Web of Science ®Google Scholar
• Zhang L, Hu Y, Chen W, Tian Y, Xie Y, Chen J. Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio is a predictor of the prognosis for brain metastases. J Neurooncol. 2020;147(3):691–700. doi:10.1007/s11060-020-03477-w
   PubMed Web of Science ®Google Scholar
• Mitsuya K, Nakasu Y, Kurakane T, Hayashi N, Harada H, Nozaki K. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis. J Neurosurg. 2017;127(2):433–437. doi:10.3171/2016.8.JNS16899
   PubMed Web of Science ®Google Scholar
• Chowdhary M, Switchenko JM, Press RH, et al. Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol. 2018;139(3):689–697. doi:10.1007/s11060-018-2914-5
   PubMed Web of Science ®Google Scholar
• Mason M, Maurice C, McNamara MG, et al. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. J Neurooncol. 2017;132(3):463–471. doi:10.1007/s11060-017-2395-y
   PubMed Web of Science ®Google Scholar
• Shaverdian N, Veruttipong D, Wang J, Schaue D, Kupelian P, Lee P. Pretreatment immune parameters predict for overall survival and toxicity in early-stage non-small-cell lung cancer patients treated with stereotactic body radiation therapy. Clin Lung Cancer. 2016;17(1):39–46. doi:10.1016/j.cllc.2015.07.007
   PubMed Web of Science ®Google Scholar
• Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104(8):1288–1295. doi:10.1038/bjc.2011.100
   PubMed Web of Science ®Google Scholar
• Lalani AA, Xie W, Martini DJ, et al. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018;6(1):5. doi:10.1186/s40425-018-0315-0
   PubMed Web of Science ®Google Scholar